4D Molecular Therapeutics (NASDAQ:FDMT) Stock: Insider David Kirn Sells 58,333 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 58,333 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $12.92, for a total value of $753,662.36. Following the transaction, the insider directly owned 709,153 shares of the company’s stock, valued at approximately $9,162,256.76. This represents a 7.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

David Kirn also recently made the following trade(s):

• On Monday, September 14th, David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $13.90, for a total value of $810,828.70.
• On Monday, August 3rd, David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.05, for a total value of $124,770.75.
• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.03, for a total value of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.87, for a total value of $548,364.96.

4D Molecular Therapeutics Trading Up 0.2%

Shares of 4D Molecular Therapeutics stock traded up $0.03 during midday trading on Wednesday, reaching $12.59. The company had a trading volume of 603,567 shares, compared to its average volume of 855,943. The stock has a fifty day moving average price of $13.61 and a 200 day moving average price of $11.34. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The firm has a market cap of $695.47 million, a PE ratio of -4.79 and a beta of 2.75. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $6.96 and a fifty-two week high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current year.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds have recently modified their holdings of FDMT. Jupiter Topco LLC acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at $76,466,000. BlackRock Inc. bought a new position in 4D Molecular Therapeutics during the second quarter worth $60,463,000. Janus Henderson Group PLC grew its holdings in 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after purchasing an additional 611,276 shares during the period. Trails Edge Capital Partners LP bought a new stake in 4D Molecular Therapeutics in the second quarter valued at $29,631,296. Finally, Bank of America Corp DE bought a new stake in 4D Molecular Therapeutics in the second quarter valued at $14,905,000. Institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on FDMT shares. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price objective on the stock in a research note on Monday, September 14th. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. The Goldman Sachs Group restated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Bank of America upped their price target on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Finally, B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $28.90.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.